Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Mammalian Transient Protein Expression Market size was valued at USD 407.48 million in 2024 and is likely to cross USD 1.09 billion by 2037, expanding at more than 7.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of mammalian transient protein expression is estimated at USD 460.61 million.
The growth of the market can be attributed primarily to the surging prevalence of chronic diseases, such as cardiovascular diseases, cancer, diabetes, kidney failure, and high blood pressure, rising demand for contamination-free and non-toxic methods, and the increasing adoption of antibodies for technological improvement in research activities. Furthermore, the transient protein in mammalian cells is used for the structural, therapeutic, and functional studies, and it is predicted to increase the market’s growth. As per the World Health Organization, cardiovascular diseases claimed the lives of 17.9 million individuals worldwide in 2019, accounting for 32% of all deaths.
Mammalian cell lines are generally used to manufacture diverse immuno- and bio-therapeutic molecules. Key manufacturers are channelizing their efforts to increase the productivity, flexibility, and throughput capabilities as well as redefine control productivity of protein production using mammalian cell lines. The growing prevalence of communicable diseases such as polio, COVID-19, and chicken pox and the increase in the diagnostic population for variant diseases have propelled the overall demand for biological therapeutics, thus providing an opportunistic push to the growth of the global mammalian transient protein expression market. According to the estimations, more than 70% of the population worldwide is administered one dose, and over 60% of the population is administered two doses of the COVID-19 vaccine.
Mammalian Transient Protein Expression Sector: Growth Drivers and Challenges
Growth Drivers
-
Increasing Geriatric Population Across the Globe to Trigger Reduction of Protein Synthesis – It was noticed the number and proportion of the geriatric population, meaning the people aged 60 years and older in the population was 1 billion in 2019 across the globe. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050.
- The rise in the geriatric population all over the world, increasing incidences of chronic diseases, infections, and seasonal illnesses, and the increasing elderly population with the presence of various diseases are responsible for the market's development over the forecast period. The protein balance of the cells is disrupted as one grow older, and the proteostasis control system that regulates the maintenance and recycling of the proteome is damaged with age and becomes inefficient. This leads to improper function of the cell following age-related dysfunctions. The use of mammalian transient protein expression can improve protein synthesis.
-
Increasing Cases of Cancer Owing to Exposure to Harmful Carcinogens – The most recurrent cases of deaths as a result of cancer were lung cancer which caused 2.21 million deaths, colon and rectum cancer, which caused 1.93 million deaths, stomach cancer, which caused 1.09 million deaths, and breast cancer, which caused 2.26 million deaths in the year 2020 across the globe.
-
Prevalence of Cancer-Causing Diseases in Low and Lower-Middle-Income Nations – It was noticed that about 30% of cancer cases in low-and lower-middle-income nations are caused by cancer-causing diseases such as the human papillomavirus (HPV) and hepatitis.
-
Increasing Health Expenditure across the Global Population – As per the data by the World Bank, as of 2019, the global current health expenditure per capita was USD 1121.97.
-
Prevalence of STDs such as AIDS among the World Population – According to the World Health Organization (WHO), since the beginning of the HIV epidemic, about 84.2 million people worldwide have been infected and about 40.1 million have lost their life. Globally, 38.4 million people were living with HIV at the end of 2021.
Challenges
- Lack of Expert Healthcare Professionals to Handle the Therapeutic Protein Generation - Mammalian transient protein expression is a rapid, cost-effective process, and on the other hand, it is a time-consuming generation that requires a highly skilled professional. Numerous samples have to be processed at the same time to benefit reproducibility. The shortage of experienced scientists is a limiting factor in market growth.
- High Cost of Implementation in Equipment and Professionals
- Risk of Contamination from Bacteria or Micro-Organisms
Mammalian Transient Protein Expression Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.9% |
|
Base Year Market Size (2024) |
USD 407.48 million |
|
Forecast Year Market Size (2037) |
USD 1.09 billion |
|
Regional Scope |
|
Mammalian Transient Protein Expression Segmentation
End-user (Contract Research Organizations, Biopharmaceutical Companies, Academic & Research Institutes)
The global mammalian transient protein expression market is segmented and analyzed for demand and supply by end user into contract research organizations, biopharmaceutical companies, and academic & research institutes. Out of these types of segments, the contract research organizations segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the rising investments in R&D activities to continuously bring up more feasible solutions across the healthcare sector. According to research reports, global research and development spending has more than tripled in real terms since 2000, rising from approximately USD 680 billion to over USD 2.5 trillion in 2019. Besides, the increasing demand for biological products, including vaccines, antibodies, and therapeutic proteins, and growing investment in the drug development sector is further expected to drive the market’s growth.
Application (Bio-production, Functional Cell-Based Assays, Academic Research)
The global mammalian transient protein expression market is also segmented and analyzed for demand and supply by application into bio-production, functional cell-based assays, academic research, and others. Amongst these segments, the bio-production segment is expected to garner a significant share. The growth of the segment can be ascribed to the higher demand for therapeutic proteins, coupled with the surging adoption of protein expression technology for the treatment of millions of patients. For instance, more than 95 genuine and modified therapeutic proteins are approved by the European Union for clinical use. Therapeutic proteins that are based on glycosylation are generally generated by the mammalian cell lines for biological activities.
Our in-depth analysis of the global market includes the following segments:
|
By Product |
|
|
By Application |
|
|
By End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportMammalian Transient Protein Expression Industry - Regional Synopsis
North American Market Forecast
North America industry is estimated to hold largest revenue share by 2037. The growth of the market can be attributed majorly to the developing healthcare infrastructure, increasing government funds to support the health industry, the growing presence of prominent players, and rising healthcare expenditure. As of 2019, healthcare expenditures in the region accounted for 16.32% of the overall regional GDP. On the other hand, the surge in the cases of AIDS and STDs is also projected to expand the market size in the region during the forecast period. The prevalence of these diseases is observed to be higher in bisexuals, men who have sex with men (MSM), and others. For instance, the percentage of MSM and men who have sex with both men and women (MSMW) was projected to be around 45% in the regional population. Additionally, the number of people in the USA suffering from HIV reached approximately 35,000 in 2022. The market is further projected to grow on the back of escalating cases of various types of cancers in the region which is increasing the requirement for effective treatment along with efficient cancer services. Data released by the Centers for Disease Control and Prevention in 2029 showed that 599,589 people lost their lives while 1,752,735 new cases of cancer were diagnosed.
Companies Dominating the Mammalian Transient Protein Expression Landscape
-
Thermo Fisher Scientific Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck KGaA
- Promega Corporation
- Lonza Group
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- QIAGEN GmbH
- Takara Bio India Pvt. Ltd.
- HiMedia Laboratories Pvt Ltd
- Sino Biological, Inc.
In the News
-
Merck KgaA announced its expansion in October 2020, with the opening of a new membrane production plant in Darmstadt, Germany. The goal was to increase the production of Millipore Express membranes, which aid in the sterility of biological drug products.
-
Agilent Technologies, Inc. to become the partner with Akoya Biosciences, Inc. to develop multiplex-immunohistochemistry diagnostic solutions. This solution will be helpful for tissue analysis to commercialize this solution.
Author Credits: Radhika Pawar
- Report ID: 4560
- Published Date: Dec 20, 2024
- Report Format: PDF, PPT
